Improved survival in MDS patients receiving iron chelation therapy - A matched pair analysis of 188 patients from the Düsseldorf MDS registry

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 1067-1070

  Neukirchen, Judith ^a   Fox, Frank ^a   Kündgen, Andrea ^a   Nachtkamp, Kathrin ^a   Strupp, Corinna ^a   Haas, Rainer ^a   Germing, Ulrich ^a   Gattermann, Norbert ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Iron chelation; Iron overload; Myelodysplastic syndrome; Survival; Transfusion therapy

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RISK; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE REGISTRY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GERMANY; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIFE EXPECTANCY; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REGISTRIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84862527526     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.006     Document Type: Article

References (8)

1. Sanz G., Nomdedeu B., Such E., Bernal T., Belkaid M., Ardanaz M.T., et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008, 112:238-239.
2. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
3. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
4. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients. A multicenter study by the GFM. Leuk Res 2010, 34:864-870.
5. Holt J.D. Competing risk analyses with special reference to matched pair experiments. Biometrika 1978, 65:159-165.
6. Sahai H., Khurshid A. Statistics and epidemiology: methods, techniques, and applications 1995, CRC Press, Boca Raton.
7. Leitch H.A., Leger C.S., Goodman T.A., Wong K.K., Wong D.H.C., Ramadan K.M., et al. Improved survival in patient with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk 2008, 3:205-211.
8. Leitch H.A. Iron chelation therapy in MDS: does it improve survival. Leuk Res 2010, 34:852-853.